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Iliofemoral stenting for venous occlusive disease
Jessica M. Titus, MD, Mireille A. Moise, MD, James Bena, MS, Sean P. Lyden, MD, and
Daniel G. Clair, MD, Cleveland, Ohio
Background: Venous hypertension is a significant cause of patient morbidity and decreased quality of life. Common
etiologies of venous hypertension include deep venous thrombosis (DVT) or congenital abnormalities resulting in
chronic outflow obstruction. We have implemented an aggressive endovascular approach for the treatment of iliac venous
occlusion with angioplasty and stenting. The purpose of this study was to determine the patency rates with this approach
at a large tertiary care center.
Materials/Methods: All patients undergoing iliofemoral venous angioplasty and stenting over a 4-year period were
identified from a vascular surgical registry. Charts were reviewed retrospectively for patient demographics, the extent of
venous system involvement, the time course of the venous pathology, and any underlying cause. Technical aspects of the
procedure including previous angioplasty or stenting attempts and presence of collaterals on completion venogram were
then recorded. Patency upon follow-up was determined using primarily ultrasound scans; other imaging methods were
used if patency was not clear using an ultrasound scan.
Results: A total of 36 patients (40 limbs) were stented from January 2005 through December 2008. Of these patients, 27
were women (75%). Both lower extremities were involved in 4 patients. Thrombolysis was performed in 19 patients
(52.8%). Thrombosis was considered acute (<30 days) in 13 patients (38%). The majority of patients who had a
recognized underlying etiology were diagnosed with May-Thurner syndrome (15 patients; 42%). In 9 patients, an
etiology was not determined (25%). The mean follow-up time period in the study population was 10.5 months. One stent
in the study occluded acutely and required restenting. Primary patency rates at 6, 12, and 24 months were 88%
(75.2-100), 78.3% (61.1-95.4), and 78.3% (61.1-95.4), respectively. Secondary patency rates for the same time frames
were 100% (100.0, 100.0), 95% (85.4, 100.0), and 95% (85.4, 100.0). Better outcomes were seen in stenting for
May-Thurner syndrome and idiopathic causes, whereas external compression and thrombophilia seemed to portend less
favorable outcomes (P < .001). Symptomatic improvement was reported in 24 of 29 patients (83%) contacted by
telephone follow-up.
Conclusion: Iliofemoral venous stenting provides a safe and effective option for the treatment of iliac venous occlusive
disease. Acceptable patency rates can be expected through short-term follow-up, especially in the case of May-Thurner
syndrome. Further experience with this approach and longer-term follow-up is necessary. Thrombophilia workup should
be pursued aggressively in this population, and further studies should be undertaken to determine the optimal length of
anticoagulation therapy after stent placement. (J Vasc Surg 2011;53:706-12.)
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tVenous outflow obstruction can lead to ambulatory
venous hypertension and chronic venous insufficiency.1-5
The symptoms of chronic venous insufficiency including
ulcerations, chronic pain, and/or swelling, are a significant
cause of morbidity and decreased quality of life for patients.
Their treatment represents a large amount of health care
expenditure, estimated at over 1 billion dollars per year.6
Common causes of outflow obstruction include acute deep
venous thrombosis (DVT) and extrinsic compression of the
iliac vein.
Chronic outflow obstruction after an episode of acute
DVT manifests itself as a constellation of symptoms known
as the postthrombotic syndrome (PTS). This includes
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706ymptoms of persistent pain, swelling, skin changes, and
lceration. As many as 29% to 82% of patients will develop
TS after an episode of DVT.7-10 These symptoms are
hought to result from the chronic outflow obstruction
fter thrombosis and occlusion of the venous lumen. Dur-
ng this process, inflammatory changes take place that can
esult in vein wall fibrosis, leading to valve dysfunction,
eflux, and insufficiency.8,11 Studies have shown that early
hrombus removal and decreasing the incidence of recur-
ent thrombotic events can reduce the likelihood of devel-
ping PTS.12-16
Chronic outflow obstruction can also result from ex-
rinsic forces compressing the iliac vein. These include
ntities such as May-Thurner syndrome (compression of
he left iliac vein from an overriding right common iliac
rtery) or pelvic tumors, fluid collections, or fibrosis.
Regardless of the cause, interventional treatment of
utflow obstruction in the form of angioplasty and stenting
as been shown to relieve symptoms and improve quality of
ife.17-19 It has also been found to have comparable if not
etter patency rates than the currently available open sur-
ical alternatives (bypass).20,21 Factors affecting stent pa-
ency rates still have not been clearly delineated. The pur-
ose of this article is to evaluate the iliofemoral venous
t
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Volume 53, Number 3 Titus et al 707stenting experience in our institution and review different
technical and clinical factors in an effort to clarify risk
factors for stent thrombosis.
MATERIALS AND METHODS
Patient factors. From January 2005 to December
2008, 36 patients were treated with venous stenting for
symptomatic iliofemoral occlusive disease. The majority of
these patients were treated within the main campus of the
institution, which serves as a large tertiary care center for
the region. A small number of patients were treated at
satellite sites, and these were also included in the study.
Both patients who presented acutely and those whose
disease was chronic were included in this study. In addition,
patients who had their initial stent placed at another hospi-
tal and subsequently presented to our institution after stent
thrombosis for further care were included, provided that
they required additional stenting. Those who did not re-
quire further stenting were not included. All patients were
studied with duplex ultrasound scans before their operation
to identify the extent of the thrombosis.
The patients’ medical charts were reviewed for demo-
graphic data, significant medical history, the extent of the
thrombosis, clinical factors, technical aspects of the surgery,
postoperative complications, and follow-up visits.
Significant medical history was divided into categories
of significant comorbidities including coronary artery dis-
ease, chronic obstructive pulmonary disease, and renal dis-
ease. Other factors recorded were current tobacco use, use
of exogenous hormones (OCPs), and a history of throm-
bophilia, malignancy, or prior vena cava filter placement.
Thrombophilia workup was performed selectively based on
surgeon evaluation for necessity. Other history reviewed
was initial treatments at another hospital and history of a
previous angioplasty attempt.
Extent of the thrombosis was judged according to
preoperative ultrasound scans and intraoperative venogra-
phy findings. Clinical factors included clinical severity and
time course of symptoms. Clinical severity was documented
according to the CEAP classification before the procedure.
Etiology of the patient’s DVT was determined based on
patient history, findings in the preoperative workup, and
intraoperative data. These were divided into 4 classes: May-
Thurner syndrome, external compression from another
source, thrombophilia, and idiopathic/unknown DVT.
The disease was considered acute if symptoms had been
present for 30 days.
Technical aspects recorded from the surgery were the
use of intravascular ultrasound (IVUS) scan, number and
size of stents used, location of stent placement, use of
thrombolysis, and concurrent filter placement. In addition,
postoperative complications were recorded.
Length of follow-up was determined by the last imag-
ing of the stent. Stent patency was recorded by date of loss
of primary, primary-assisted, or secondary patency.
Procedure. Access was gained proximal to the level of
the obstruction from a venous flow standpoint. This was
the popliteal vein in the majority of the patients (20 pa- cients). Femoral access was used in 13 patients, and
patients had a combined femoral/jugular approach.
enography was then performed to discern the extent of
he thrombosis or obstruction. In all patients, balloon
ngioplasty was attempted before stents were placed. After
ngioplasty, the presence of recoil or persistent obstruction
rompted the use of stents. A variety of nitinol self-expand-
ng stents were used in the majority of patients, and size was
ased on the vessel in which it was deployed. Two patients
ad steel self-expanding stents placed. Median stent diam-
ter was 14 mm (range, 9-28). Completion venography
as then obtained to identify the presence of persistent
ollaterals or the need for further stenting. Fig 1 shows a
epresentative ultrasound scan and venograms. Inferior
ena cava (IVC) filter placement was used selectively in
atients who were felt to be at a very high risk for pulmo-
ary embolus based on individual surgeon assessment. In
hese cases, retrievable filters were used.
Postoperatively, all patients were started or continued
n anticoagulation therapy with warfarin (goal-interna-
ional normalized ratio 2-3) or Lovenox for at least 6
onths. Follow-up imaging was primarily done with du-
lex ultrasound scan. A small number of patients were
eimaged with computed tomography, magnetic resonance
maging, and/or repeat venography because of difficulty
btaining adequate imaging of the stents by ultrasound
can alone. No follow-up data were available for 3 patients.
atients were contacted by telephone at the time of this
tudy. They were asked about their overall current symp-
oms, their edema on an average day, and if they had
ndergone any subsequent operations with respect to their
enous occlusive disease.
Statistical methods. Data were summarized using
requencies and percentages for categorical factors and
ean, SD, and percentiles of interest for continuous mea-
ures. For purposes of analysis, the number of stents was
educed to 1, 2, and 3 ormore. The stent size was evaluated
s the maximum diameter. Measures of patency at 6
onths, 1 year, and 2 years, were calculated using Kaplan-
eier estimation. Estimates and comparisons of risk across
roups defined by baseline characteristics were evaluated
sing Cox proportional hazards models. Statistical analysis
as performed using SAS software (version 9; Cary, NC),
nd plots were created using R Software (version 2; Vienna,
ustria). A significance level of 0.05 was assumed for all
ests.
ESULTS
During the time period listed, 88 iliofemoral venous
ngioplasties were performed. Of these, 36 patients under-
ent lower extremity venous stenting for occlusive disease.
n total, 40 limbs were stented, as 4 patients (11%) had
ilateral lower extremity involvement. Of these patients, 27
ere women (75%). The average age was 45.6 years old
range, 17-73). The occlusion was considered acute in 14
f those patients (39%) presenting for treatment. In the
ategories of defined etiology of the occlusion (Fig 2), 15
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March 2011708 Titus et alpatients had May-Thurner syndrome (41.7%), 9 patients
had an idiopathic/unknown cause (25%), 7 patients had
external compression (19.4%), and 5 patients (13.9%) had a
known underlying thrombophilia. Of those in the external
compression category, 2 patients had postoperative lym-
phoceles after pelvic lymph node dissections for prostate
cancer, 1 patient had retroperitoneal fibrosis, and 4 patients
had malignancy-related compression. Of these 4 patients, 3
had mass effect from enlarged lymph nodes from testicular,
prostate, or cervical cancer, and 1 had direct compression
from a large sarcoma. In 14 patients (39%), thrombophilia
workup was performed resulting in eight positive findings
(22% of study patients, 57% of those checked). Of those
positive findings, 4 patients had factor V Leiden heterozy-
gosity, 2 patients had lupus anticoagulant, 2 patients were
positive for prothrombin 20210A mutation, and 2 patients
Fig 1. Ultrasound scans and venograms of a 49-year-
extremity swelling and pain. A, Initial ultrasound scan sh
left external iliac vein. B, Initial venogram shows stenose
inferior vena cava (IVC) mainly through cross-pelvic col
films, and residual stenosis was noted as well. D, Postste
flow through the femoral and iliac system into the IVC.were found to have MTHFR factor II mutation. One of ohese patients had both factor V Leiden and lupus antico-
gulant, and another had both a prothrombin gene muta-
ion and factor V Leiden.
Medical history and other demographic factors are
hown in Table I. Mean CEAP clinical severity score on
nitial presentation was 3.25. Actual distribution of the
lasses can be seen in Table II. Five patients (13.9%) had
een seen and treated with stenting at another institu-
ion, and 9 patients (25%) had IVC filters placed before
eing seen by a vascular surgeon in our department. In
his study, 12 patients (33%) had a previous angioplasty
ttempt (at either our institution or another hospital)
hat had failed. Clot burden was isolated to the left side
n 24 patients (66.7%), the right side in 7 patients
19.4%), and bilateral in 4 patients (11%). IVC involve-
ent was noted in 12 patients (33%), femoral veins were
emale smoker who presented with chronic left lower
noncompression (left) and compression (right) views of
eft common femoral vein and iliac system with filling of
ls. C, Collateral filling persisted on the postangioplasty
nogram shows resolution of collateral filling with goodold f
ows
s of l
latera
nt veccluded in 26 patients (19 left, 6 right, and 1 bilateral),
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Fig 2. Underlying eti
Table I. Demographic and comorbidities of patient
population
Demographic/comorbidity No. (%)
CAD 7 (19%)
COPD 3 (8%)
Renal disease 2 (6%)
Current smoker 9 (25%)
Thrombophilia workup 14 (39%)
Positive 8 (22%)
Negative 6 (17%)
Acute disease 14 (39%)
Initial stent at other institution 5 (14%)
On anticoagulation 23 (64%)
CAD, Coronary artery disease; COPD, chronic obstructive pulmonary dis-
ease.
Table II. CEAP clinical severity score comparison at
presentation and follow-up poststent
CEAP clinical severity score
Presentation Follow-up
Score No. (%) Score No. (%)
0-1 0 0-1 12 (33%)
2 2 (6%) 2 2 (6%)
3 25 (69%) 3 19 (53%)
4 8 (22%) 4 0
5 0 5 1 (3%)
6 1 (3%) 6 0patients (38.9%). uInitial thrombolysis was done in 19 patients (52.8%),
hich took place for 12 to 72 hours. Three of the 19
atients had residual clot present at the cessation of throm-
olysis. In all, 73 stents were placed in 40 limbs. The largest
umber of stents in 1 patient was seven. One stent was
laced in each of 13 patients (36.1%), 2 stents were placed
n each of 14 patients (38.9%), and 3 stents were placed in
ach of 9 patients (25%). Stent placement involved the left
ommon iliac in 24 patients, right common iliac in 6
atients, and bilateral common iliacs in 3 patients. Left,
ight, and bilateral external iliacs were stented in 19, 4, and
patients, respectively. In 20% of the patients, the femoral
ein was also stented. IVUS was used in 10 cases (27.7%).
ine patients had previously placed IVC filters from other
nstitutions; two of these were removed. Of the two IVC
lters placed by our surgeons, one was removed with the
atient being lost to follow-up before the filter could be
emoved.
Postoperatively, one stent had early thrombosis and
equired acute reoperation. Otherwise, there were no com-
lications associated with the stenting; no incidences of
ulmonary embolus were recorded and no bleeding com-
lications were noted. Primary patency rates (shown in Fig
) at 6, 12, and 24 months were 88% (75.2-100), 78.3%
61.1-95.4), and 78.3% (61.1-95.4), respectively. Second-
ry patency rates for the same time frames were 100%
100.0, 100.0), 95% (85.4, 100.0), and 95% (85.4, 100.0),
espectively. Mean follow-up time was 10.5 months with a
ange of 0 to 38months. At follow-up, mean CEAP clinical
everity score had decreased to 1.97. One patient in this
tudy had venous ulceration preoperatively; upon follow-
of venous occlusion.p, this had healed.
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March 2011710 Titus et alWith regard to risk factors for in-stent stenosis or
rethrombosis, only etiology of the obstruction was deter-
mined to be a statistically significant factor (Table III).
Patients with external compression or associated thrombo-
philia were more likely to have a worse outcome than those
with May-Thurner syndrome or idiopathic occlusion (P 
.001). Other variables measured that were not determined
to be statistically significant were stent placement in the
femoral system, stent diameter, stent placement into the
IVC, the use of IVUS scan, number of stents, and acute-
vs-chronic disease presentation.
On telephone call follow-up, 29 patients were reached.
Three patients had expired and 4 patients were unavailable.
All patients who were contacted elected to participate in
this study. Of these 29 patients, 24 (83%) reported an
overall improvement in their symptoms because they had
undergone stenting. Two patients reported that their
symptoms had not changed (7%), and 3 patients stated that
their symptoms had become progressively worse (10%).
With respect to edema, 7 patients (24%) rated it as none, 11
patients (40%) as mild, 8 patients (28%) as moderate, and 3
patients (10%) as severe.
DISCUSSION
Results from this small retrospective study show that
excellent patency rates and symptomatic improvement can
be obtained with stenting for venous outflow occlusion.
Fig 3. In-graph patency estimates for the entire cohort are pro-
vided. Kaplan-Meier estimates of primary, assisted primary, and
secondary patency are provided with 95% confidence intervals in
parentheses are shown below.
Measures
Frequ-
ency Events 6 months 12 months 24 months
Primary
patency
36 5 88.1 (75.2-100.0) 78.3 (61.1-95.4) 78.3 (61.1-95.4)
Assisted
primary
patency
36 4 92.5 (82.3-100.0) 82.7 (67.0-98.4) 82.7 (67.0-98.4)
Secondary
patency
36 1 100.0 (100.0-100.0) 95.0 (85.4-100.0) 95.0 (85.4-100.0)Our primary and secondary patency rates at 2 years of 78% mnd 95%, respectively, are comparable to those found by
revious studies.17,22-25 Primary patency was lost in 5
atients at mean follow-up of 10 months, all but one of
hese stents were able to be reopened. In the last patient,
nother operation was refused by the patient and actually
ot recommended by the surgeon, as the patient’s symp-
oms of edema, claudication, and skin changes were im-
roving.
Other studies have divided the etiologies into throm-
otic and nonthrombotic disease, but to our knowledge,
o study has looked at the different causes of thrombotic
isease to discern its effect on stent outcome. This study
howed a worse outcome with etiologic factors of diag-
osed thrombophilia and external compression as opposed
o May-Thurner syndrome or idiopathic causes. Of the
tents that lost primary patency, 2 patients had diagnosed
hrombophilia and 3 had external compression as the un-
erlying etiologies. Two of the patients in the external
ompression group occluded their stents within a month of
eing taken off their anticoagulation. One of the 2 patients
as subsequently found to have an underlying thrombo-
hilia. Once anticoagulation was restarted, there were no
urther problems. This brings forward the question of how
ong to continue anticoagulation in people with venous
tents and whether to pursue a hypercoagulable workup
ore frequently in this patient population.
Limitations of the study were the small patient size and
imited follow-up. Venous stenting is becomingmore com-
onplace at our institution and with education of other
pecialists and primary care physicians, referrals should in-
rease and allow us to gain better information with a larger
atient pool. In addition, within our department, we have
egun to implement specific guidelines for standard follow-up
f these patients concerning office visits and imaging. This
hould ensure better follow-up. The small number of events
f stent occlusion in the study also made it difficult to
etermine any statistically significant risk factors for stent
cclusion. This highlights the need for additional studies,
ossibly multicenter with larger numbers of patients.
Interestingly, all but 1 of the patients in this study
ere referred or seen for symptoms associated with
urrent clot burden. Only 1 patient was referred solely for
TS evaluation. Studies have shown that PTS symptoms
an be improved with stenting, as they usually have at least
artial outflow occlusion and associated venous hyperten-
ion. The referral findings in this study highlight the need
or education of other health professionals in this institu-
ion, as there are likely more patients that can be helped
ith this therapy.
In summary, the results of this study indicate that
enous stenting for iliofemoral occlusive disease is a safe
nd effective method of treatment. It can be done with
xcellent patency rates expected in cases of idiopathic oc-
lusion and May-Thurner syndrome. However, in cases in
hich external compression or inherent thrombophilia is
he cause of the underlying occlusion, poorer outcomes can
e expected. Relief of patient symptoms continues to be the
ain goal of treatment. Venous stenting has been shown
11
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Volume 53, Number 3 Titus et al 711in this study to be a very good means of achieving that
goal. In addition, perhaps a more aggressive approach
toward hypercoagulability assessment should be pursued
in this patient population and studies to determine the
optimal duration of anticoagulation therapy after venous
stenting are needed.
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